Business
Medicure Announces Positive Results for AGGRASTAT® in the FABOLUS-FASTER Trial and Publication in the Journal - Circulation
Medicure Announces Positive Results for AGGRASTAT® in the FABOLUS-FASTER Trial and Pu...
About this update from Medicure Inc.
[{"type":"text","content":"\n\n\n\nMedicure Announces Positive Results for AGGRASTAT® in the FABOLUS-FASTER Trial and Publication in the Journal - Circulation\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nWINNIPEG, MB, June 29, 2020\n\n\n\nWINNIPEG, MB, June 29, 2020 /CNW/ - Medicure Inc. (\"Medicure\" or the \"Company\") (TSXV: MPH) (OTC: MCUJF), a pharmaceutical company, today announced that results from the investigator sponsored FABOLUS-FASTER Phase 4 clinical trial, using AGGRASTAT®, have been published in Circulation, a peer-reviewed journal of the American Heart Association. \nFABOLUS-FASTER studied different regimens of intravenous platelet inhibitors, notably AGGRASTAT® (tirofiban hydrochloride) injection (an IV GP IIb/IIIa inhibitor) and cangrelor (an IV P2Y12 inhibitor) in the early phase of primary PCI.\n\"The results published in Circulation are the first to compare the pharmacodynamic effects of cangrelor, with AGGRASTAT®, as well as the pharmacodynamic and pharmacokinetic effects of a chewed or integral pill of prasugrel,\" said Dr. Albert D. Friesen, CEO of Medicure. \"We are pleased with the performance of AGGRASTAT® in the FABOLUS-FASTER trial against cangrelor and look forward to its continued growth as part of our portfolio of cardiovascular products.\"\nThe FABOLUS-FASTER study randomized 122 P2Y12-naive STEMI patients to receive tirofiban (n=40), cangrelor (n=40), or a 60 mg loading dose of prasugrel (n=42). Those randomized to prasugrel were sub-randomized to chewed (n=21) or integral (n=21) tablet administration. The study was powered to test the noninferiority of cangrelor compared with tirofiban, the superiority of both tirofiban and cangrelor compared with chewed prasugrel, and superiority of chewed prasugrel compared with integral prasugrel for the primary endpoint of 30-minute inhibition of platelet aggregation (IPA) after stimulation with (20 µmol/L) ADP. \nThe results from the FABOLUS-FASTER trial showed cangrelor did not reach non-inferiority with tirofiban; in fact, tirofiban achieved super...